focus on the United States, Japan, France, Germany, Italy, Spain and the United Kingdom – .

focus on the United States, Japan, France, Germany, Italy, Spain and the United Kingdom – .

DUBLIN, October 19, 2021– (BUSINESS WIRE) – The report “Plaque Psoriasis – Epidemiology Forecast to 2030” has been added to offer.
Plaque psoriasis is the most common form of psoriasis, affecting between 80% and 90% of people with psoriasis, and can occur on any area of ​​the body such as the scalp, hands, and feet (National Psoriasis Foundation, 2018).

The editor epidemiologists relied on the strongest country-specific data for each segmentation covered in this forecast, obtained from scientific studies published in peer-reviewed academic journals, international health agency publications, National neonatal registries and national disease surveillance agencies available at the time. publication.

This report includes a 10-year forecast of prevalent cases of plaque psoriasis diagnosed for life between 2020 and 2030. Common cases of plaque psoriasis are then segmented by sex and age. The data on plaque psoriasis are then segmented by severity (mild, moderate and severe) and by case of plaque psoriasis with psoriatic arthritis.

In the 7MM, the number of prevalent cases of plaque psoriasis diagnosed during the lifetime will increase from 15,726,350 in 2020 to 16,856,548 in 2030, at an annual growth rate (AGR) of 0.72% per year. Likewise, the prevalent cases of lifelong diagnosed psoriasis in the 5 EU (France, Germany, Italy, Spain and UK) will increase at an AGR of 0.55%, from 7,779,141 in 2020 to 8 210,874 in 2030.

Looking at the AGR by individual market, the publisher estimates that the United States will have the highest number of cases of plaque psoriasis in 2030, with 8,171,859 cases at an AGR of 0.93%. Conversely, Japan will have the fewest cases by 2030, with 473,815 cases at an AGR of 0.08%.


  • The Multiple Psoriasis Epidemiology Report provides an overview of the global and historical risk factors, comorbidities and trends for multiple psoriasis in the top seven markets (7MM) (United States, France, Germany, Italy, Spain, United Kingdom and Japan).
  • The report includes a 10-year epidemiological forecast for prevalent cases diagnosed with plaque psoriasis throughout life, segmented by sex and age (0-17 years, 18-29 years, and 10-year age groups for 30 to 80 years and older) in these markets. The prevalent cases diagnosed during life are further segmented by severity and cases of plaque psoriasis with psoriatic arthritis in the adult population.
  • The MS and PhD Epidemiology Report is written and developed by epidemiologists with masters and doctorates.
  • The epidemiological report is in-depth, high-quality, transparent and market-driven, providing expert analysis of disease trends in plaque psoriasis.

Main topics covered:

1 Plaque psoriasis: executive summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Context of the disease

2.1.1 Risk factors and co-morbidities

2.2 Global and historical trends

2.3 Forecasting methodology

2.3.1 Sources

2.3.2 Assumptions and forecasting methods

2.4 Epidemiological Forecast for Plaque Psoriasis (2020-2030)

2.4.1 Prevalent cases diagnosed during the lifetime of plaque psoriasis

2.4.2 Prevalent cases of plaque psoriasis diagnosed during life by age

2.4.3 Prevalent cases of plaque psoriasis diagnosed during life by sex

2.4.4 Prevailing Lifetime Diagnosis of Severity Plaque Psoriasis in the Adult Population

2.4.5 Prevailing Lifetime Diagnosis of Plaque Psoriasis with RP in the Adult Population

2.5 Discussion

2.5.1 Overview of epidemiological forecasts

2.5.2 Impact of COVID-19

2.5.3 Limitations of the analysis

2.5.4 Strengths of the analysis

3 Annex

For more information on this report, visit

View the source version on

Laura Wood, Senior Press Director
[email protected]

For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900


Please enter your comment!
Please enter your name here